Huntington National Bank Buys 117 Shares of Illumina, Inc. (NASDAQ:ILMN)

Huntington National Bank boosted its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 29.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 515 shares of the life sciences company’s stock after purchasing an additional 117 shares during the quarter. Huntington National Bank’s holdings in Illumina were worth $67,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Versant Capital Management Inc raised its stake in shares of Illumina by 292.9% during the 2nd quarter. Versant Capital Management Inc now owns 330 shares of the life sciences company’s stock worth $34,000 after acquiring an additional 246 shares in the last quarter. Industrial Alliance Investment Management Inc. purchased a new position in Illumina in the second quarter worth $34,000. Massmutual Trust Co. FSB ADV increased its position in shares of Illumina by 65.1% during the third quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company’s stock worth $56,000 after purchasing an additional 168 shares in the last quarter. Itau Unibanco Holding S.A. acquired a new position in shares of Illumina during the second quarter worth $61,000. Finally, Mizuho Securities Co. Ltd. purchased a new stake in shares of Illumina during the 2nd quarter valued at $63,000. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Analysts Set New Price Targets

ILMN has been the topic of several recent analyst reports. Scotiabank reduced their target price on Illumina from $176.00 to $164.00 and set a “sector outperform” rating on the stock in a research report on Thursday, August 15th. Canaccord Genuity Group upped their price objective on shares of Illumina from $130.00 to $145.00 and gave the company a “hold” rating in a report on Tuesday, November 5th. Royal Bank of Canada increased their price objective on shares of Illumina from $252.00 to $254.00 and gave the company an “outperform” rating in a research report on Tuesday, November 5th. HSBC raised shares of Illumina from a “hold” rating to a “buy” rating and set a $180.00 target price on the stock in a research report on Thursday, October 17th. Finally, Robert W. Baird boosted their price target on Illumina from $124.00 to $139.00 and gave the company a “neutral” rating in a research note on Wednesday, November 6th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, fourteen have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Illumina has a consensus rating of “Moderate Buy” and an average price target of $164.00.

Illumina Trading Down 3.2 %

Shares of ILMN stock opened at $130.74 on Tuesday. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.43 and a quick ratio of 1.85. The stock has a 50 day simple moving average of $139.82 and a 200-day simple moving average of $124.35. The company has a market cap of $20.74 billion, a price-to-earnings ratio of -13.13 and a beta of 1.13. Illumina, Inc. has a 1-year low of $93.39 and a 1-year high of $156.66.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.88 by $0.26. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. The firm had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.08 billion. During the same period in the previous year, the company posted $0.33 earnings per share. The business’s revenue was down 3.5% on a year-over-year basis. On average, equities research analysts expect that Illumina, Inc. will post 4.11 EPS for the current fiscal year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.